NasdaqGS - Nasdaq Real Time Price USD

MacroGenics, Inc. (MGNX)

Compare
3.1800 0.0000 (0.00%)
At close: December 20 at 4:00:02 PM EST
3.2390 +0.06 (+1.86%)
After hours: 7:00:31 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
139,773.0000
57,193.0000
150,018.0000
75,643.0000
97,764.0000
Cost of Revenue
6,972.0000
8,222.0000
7,384.0000
2,651.0000
--
Gross Profit
132,801.0000
48,971.0000
142,634.0000
72,992.0000
97,764.0000
Operating Expense
239,896.0000
217,215.0000
264,052.0000
275,787.0000
228,824.0000
Operating Income
-107,095.0000
-168,244.0000
-121,418.0000
-202,795.0000
-131,060.0000
Net Non Operating Interest Income Expense
9,478.0000
8,256.0000
1,660.0000
680.0000
--
Other Income Expense
1,055.0000
150,930.0000
1,660.0000
680.0000
1,321.0000
Pretax Income
-97,617.0000
-9,058.0000
-119,758.0000
-202,115.0000
-129,739.0000
Net Income Common Stockholders
-97,617.0000
-9,058.0000
-119,758.0000
-202,115.0000
-129,739.0000
Diluted NI Available to Com Stockholders
-97,617.0000
-9,058.0000
-119,758.0000
-202,115.0000
-129,739.0000
Basic EPS
-1.57
-0.15
-1.95
-3.37
-2.47
Diluted EPS
-1.57
-0.15
-1.95
-3.37
-2.47
Basic Average Shares
62,436.1220
61,929.1980
61,433.1240
59,944.7170
52,442.3890
Diluted Average Shares
62,436.1220
61,929.1980
61,433.1240
59,944.7170
52,442.3890
Total Operating Income as Reported
-107,095.0000
-168,244.0000
-121,418.0000
-202,795.0000
-131,060.0000
Total Expenses
246,868.0000
225,437.0000
271,436.0000
278,438.0000
228,824.0000
Net Income from Continuing & Discontinued Operation
-97,617.0000
-9,058.0000
-119,758.0000
-202,115.0000
-129,739.0000
Normalized Income
-97,617.0000
-159,988.0000
-119,758.0000
-202,115.0000
-129,739.0000
Interest Income
10,617.0000
9,686.0000
1,660.0000
680.0000
--
Interest Expense
1,139.0000
1,430.0000
--
--
--
Net Interest Income
9,478.0000
8,256.0000
1,660.0000
680.0000
--
EBIT
-96,478.0000
-7,628.0000
-119,758.0000
-202,115.0000
-131,060.0000
EBITDA
-89,091.0000
2,017.0000
-107,893.0000
-190,857.0000
-119,103.0000
Reconciled Cost of Revenue
6,972.0000
8,222.0000
7,384.0000
2,651.0000
--
Reconciled Depreciation
7,387.0000
9,645.0000
11,865.0000
11,258.0000
11,957.0000
Net Income from Continuing Operation Net Minority Interest
-97,617.0000
-9,058.0000
-119,758.0000
-202,115.0000
-129,739.0000
Total Unusual Items Excluding Goodwill
--
150,930.0000
--
--
--
Total Unusual Items
--
150,930.0000
--
--
--
Normalized EBITDA
-89,091.0000
-148,913.0000
-107,893.0000
-190,857.0000
-119,103.0000
12/31/2020 - 10/10/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRSN Mersana Therapeutics, Inc.
1.6000
-8.05%
 
KPTI Karyopharm Therapeutics Inc.
0.6350
-2.25%
 
ANRO Alto Neuroscience, Inc.
3.8900
+4.57%
 
IMCR Immunocore Holdings plc
28.33
-0.33%
 
XNCR Xencor, Inc.
24.13
+0.50%
 
CTMX CytomX Therapeutics, Inc.
1.0900
-0.91%
 
ZNTL Zentalis Pharmaceuticals, Inc.
3.0000
+2.39%
 
FGEN FibroGen, Inc.
0.4000
+13.09%
 
ATRA Atara Biotherapeutics, Inc.
11.40
+14.80%
 
GBIO Generation Bio Co.
1.1900
+10.19%